Navigation Links
In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop
Date:10/7/2008

CAMBRIDGE, Mass., Oct. 7 /PRNewswire/ -- Taligen Therapeutics Inc. today announced that in vivo data on several of the Company's pipeline candidates were presented at the XXII International Complement Workshop in Basel, Switzerland. The data highlighted the candidates' efficacy in several animal models of complement-mediated diseases.

"These highlighted presentations, as well as several in vitro studies presented at the conference, reveal the deep expertise and expanding knowledge base within the complement research community," said Michael Holers, M.D., chief scientific officer of Taligen Therapeutics. "The work, not only from our laboratory but from the laboratories of our collaborators, is unlocking the mechanisms of immunomodulation and enabling Taligen to direct the development of new product candidates and test them in a variety of animal models as a precursor to their clinical development."

"The opportunity to further evaluate Taligen's TT30 compound in our research activities has been invaluable in our characterization of the effects of modulation of the complement system on animal models of human disease," said Steve Tomlinson, Ph.D. and principal investigator of several studies presented at the complement meeting. "Our results in the MRL lupus model in collaboration with Dr. Gary Gilkeson's group now show that targeted complement inhibition using TT30 leads to both local control of inflammation as well as a substantial decrease in the autoimmune response in vivo. No other type of compound has this dual profile of activity. I also believe these CR2-targeted compounds will help future research in the lupus area and hopefully provide therapeutic options for patients."

Key findings from several of the studies testing Taligen's product candidates are highlighted below:

Data support targeting the alternative complement pathway using TT30 as an immunomodulatory compound for treating complement-mediated diseases

In vivo studies in models for several complement-mediated diseases showed that targeted inhibition of the alternative complement pathway slowed or halted disease progression in these models. Sekine et al. investigated whether TT30 prevented progression of renal disease in a lupus nephritis murine model (Poster #174). TT30 is a fusion protein coupling domains from complement receptor 2 (CR2) with the alternative pathway inhibitor factor H (fH). Treatment with the CR2 domain alone led to decreases in autoantibodies, while treatment with TT30 resulted in additional beneficial effects including significantly reduced renal injury, proteinuria and anti-dsDNA antibody levels compared to controls. Therefore, the dual action of TT30 (CR2 and fH) prevented disease progression in this animal model.

Thurman et al. (Poster #171) compared the effect of systemic administration of TT30 to the effect of CR2-Crry in an airway hyper-responsiveness asthma animal model. CR2-Crry is an inhibitor of the alternative, classical and lectin complement pathways whereas TT30 inhibits only the alternative pathway. The study showed that both TT30 and CR2-Crry significantly reduced airway hyper-responsiveness. This suggests that targeting the alternative complement pathway, while keeping the classical and lectin complement pathways unaffected, may be sufficient to control complement-mediated diseases and thus reduce the risk of infection.

Wet AMD animal model study suggests an alternative to intraocular drug administration

Currently marketed therapies for wet AMD require intraocular injections. In a wet AMD animal model, Rohrer et al. (Poster #202) tested whether TT30 could be effective in preventing progression of choroidal neovascularization following argon laser photocoagulation if TT30 was injected intraocularly or intravenously. The Rohrer team demonstrated that TT30 prevented progression of choroidal neovascularization regardless of the mode of administration. Besides adding further confirmation to the therapeutic potential of targeting the alternative pathway in complement-mediated diseases, the study showed intravenous administration of TT30 could specifically target a site of complement activation and be an effective alternative to intraocular injections.

Growing pipeline

Additional In vivo data were presented for CR2-Crry, a previously undisclosed Taligen pipeline candidate. CR2-Crry is a fusion protein combining CR2 with Crry, a murine analogue of human complement receptor 1 (CR1), which appears to inhibit all three complement pathways. Atkinson et al. showed in a myocardial ischemia/reperfusion injury study (Poster #196) that single doses of CR2-Crry and TT30 were equivalent in protecting heart grafts from ischemia/reperfusion injury. However, when both compounds were tested for their effectiveness in preventing antibody-mediated graft rejection, multiple doses of CR2-Crry were superior to TT30 in increasing graft survival. The study showed the critical importance of the alternative complement pathway in ischemia-reperfusion injury but also highlighted the role of the classical and lectin pathways in antibody-mediated rejection.

About Taligen Therapeutics

Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that are designed to modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The Company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. Taligen's headquarters and late-stage research and development operations are located in Cambridge, Mass. The company also maintains a drug discovery operation in Denver that is closely aligned with an international complement biology research network organized by Michael Holers, M.D., one of the Company's founders. For more information, visit http://www.taligentherapeutics.com.

This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to efficacy of the Company's product candidates and potential advantages of the Company's technology and product candidates. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in this release.

Media Contacts:

Robert Flamm, Ph.D. or David Schull

Russo Partners

(212) 845-4226

robert.flamm@russopartnersllc.com

david.schull@russopartnersllc.com


'/>"/>
SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
2. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
3. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
4. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
5. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
6. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
(Date:12/2/2016)... -- bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, ... von Kenia eingeführt. Continue Reading ... ... (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die Clinton ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
(Date:11/30/2016)... ... 30, 2016 , ... Standard Process, Inc. is proud to ... recognition of the largest closely held companies headquartered in Wisconsin. This marks the ... Standard Process was awarded the Talent Award for providing outstanding employee benefits. ...
Breaking Medicine News(10 mins):